Objective:
To explore the potential of subretinal RPE cell transplantation derived from human embryonic stem cells in restoring vision in patients with advanced geographic atrophy (GA), specifically focusing on functional recovery.
Key Findings:
- Treated eyes showed improvements in BCVA at 26 weeks across all dose cohorts, while untreated fellow eyes generally declined.
- Mean BCVA change from baseline was +10.5 letters (low-dose), +7.25 letters (medium-dose), and +4.25 letters (high-dose) compared to declines of -4.0, -5.65, and +2.56 letters in untreated eyes.
- Visual gains persisted at 52 weeks in available follow-up data, with +5.5 letters (low-dose) and +9.08 letters (medium-dose) compared to declines in untreated eyes.
- GA lesion size remained stable in treated eyes, while untreated eyes showed progressive degeneration.
- No significant safety concerns were reported, aside from one serious adverse event.
Interpretation:
The findings suggest that regenerative stem cell therapy may not only preserve but also partially restore vision in patients with advanced GA, marking a potential shift in treatment strategies towards recovery rather than just preservation.
Limitations:
- The study is early and ongoing, with a small sample size.
- Long-term effects and durability of visual gains remain to be fully evaluated, necessitating further research.
Conclusion:
Regenerative stem cell therapy introduces a novel approach to potentially restore vision in advanced GA, contrasting with traditional therapies focused solely on slowing degeneration.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.